News & Updates

Show Multimedia Only

Trastuzumab shots for breast cancer deliver on cost savings

07 Dec 2024 by

Subcutaneous trastuzumab may be a cost-saving alternative to the intravenous formulation in the treatment of breast cancer patients in Singapore, according to a study.

Trastuzumab shots for breast cancer deliver on cost savings

07 Dec 2024

Clinical considerations for patients at high risk for progression to severe COVID-19

07 Dec 2024

COVID-19 has not gone away. New contagious variants continue to be a leading cause of death, with underlying conditions still influencing the risk of COVID-19 hospitalizations, said Dr Ali Hassoun, Clinical Professor of Medicine and infectious disease specialist at Crestwood Medical Center, Huntsville, Alabama, US, who spoke at a Pfizer-sponsored session during IDWeek 2024.

Clinical considerations for patients at high risk for progression to severe COVID-19

07 Dec 2024

RSV places strain on HK’s public health system, but vaccination reduces burden

06 Dec 2024 by

Respiratory syncytial virus (RSV)-associated infections in older adults impose a substantial economic burden on Hong Kong’s public health system, but the good news is that this burden may be mitigated by vaccination.

RSV places strain on HK’s public health system, but vaccination reduces burden

06 Dec 2024

Less cannabis use helps improve functional outcomes

06 Dec 2024

A decrease in the use of cannabis results in clinician-assessed improvement among individuals with cannabis use disorder, suggests a study.

Less cannabis use helps improve functional outcomes

06 Dec 2024

High-risk opioid use prevalent in patients with haematologic malignancy

06 Dec 2024

Many adult patients with haematologic malignancies (HM) have high-risk opioid use, which can increase their risk of opioid-related harms, reveals a study.

High-risk opioid use prevalent in patients with haematologic malignancy

06 Dec 2024

Original New Drug Application Approvals by US FDA (16-30 November 2024)

06 Dec 2024

New drug applications approved by US FDA as of 16-30 November 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 November 2024)

06 Dec 2024

TRT shows promise as adjunct treatment in rehabilitating ICU patients

05 Dec 2024 by

Testosterone replacement therapy (TRT) has the potential to be an effective adjunct treatment in the rehabilitation of critically ill patients with intensive care unit (ICU)-associated weakness (AW) and hospital-associated deconditioning (HAD), according to a Singapore study.

TRT shows promise as adjunct treatment in rehabilitating ICU patients

05 Dec 2024

What drives the beneficial effects of tirzepatide on glycaemic control?

05 Dec 2024

Use of tirzepatide results in better glycaemic control when compared with semaglutide, as shown by improved fasting glucose and glucose excursion control brought about by improvements in insulin secretion rate (ISR), insulin sensitivity, and glucagon suppression, according to a study.

What drives the beneficial effects of tirzepatide on glycaemic control?

05 Dec 2024

Benralizumab offers relief during eosinophilic asthma, COPD flare-ups

04 Dec 2024 by

A single subcutaneous injection of benralizumab, administered alone or in combination with glucocorticoids, helps minimize treatment failure and improve symptoms in patients with an eosinophilic exacerbation of asthma or chronic obstructive pulmonary disorder (COPD), as shown in the phase II ABRA trial.

Benralizumab offers relief during eosinophilic asthma, COPD flare-ups

04 Dec 2024

Fezolinetant eases symptoms in menopausal women unfit for hormone therapy

04 Dec 2024 by

Use of fezolinetant demonstrates efficacy and good tolerability in the treatment of moderate-to-severe vasomotor symptoms associated with menopause in women who are deemed unsuitable for hormone therapy, reports a study.

Fezolinetant eases symptoms in menopausal women unfit for hormone therapy

04 Dec 2024

News & Updates

Filter by Specialty:

Specialty:

Trastuzumab shots for breast cancer deliver on cost savings

Trastuzumab shots for breast cancer deliver on cost savings

Clinical considerations for patients at high risk for progression to severe COVID-19

Clinical considerations for patients at high risk for progression to severe COVID-19

RSV places strain on HK’s public health system, but vaccination reduces burden

RSV places strain on HK’s public health system, but vaccination reduces burden

Less cannabis use helps improve functional outcomes

Less cannabis use helps improve functional outcomes

High-risk opioid use prevalent in patients with haematologic malignancy

High-risk opioid use prevalent in patients with haematologic malignancy

Original New Drug Application Approvals by US FDA (16-30 November 2024)

Original New Drug Application Approvals by US FDA (16-30 November 2024)

TRT shows promise as adjunct treatment in rehabilitating ICU patients

TRT shows promise as adjunct treatment in rehabilitating ICU patients

What drives the beneficial effects of tirzepatide on glycaemic control?

What drives the beneficial effects of tirzepatide on glycaemic control?

Benralizumab offers relief during eosinophilic asthma, COPD flare-ups

Benralizumab offers relief during eosinophilic asthma, COPD flare-ups

Fezolinetant eases symptoms in menopausal women unfit for hormone therapy

Fezolinetant eases symptoms in menopausal women unfit for hormone therapy